Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID‐19 vaccine: Successful treatment with ustekinumab and acitretin.

Autor:	Gamonal, Shirley Braga Lima, Marques, Nathália Couri Vieira, Pereira, Heitor Motta Bini, Gamonal, Aloisio Carlos Couri
Předmět:	PITYRIASIS rubra COVID-19 vaccines TREATMENT effectiveness MESSENGER RNA VACCINATION complications
Zdroj:	Dermatologic Therapy; Dec2022, Vol. 35 Issue 12, p1-3, 3p
Abstrakt:	Pityriasis rubra pilaris (PRP) is a rare erythematous papulosquamous disorder, clinically and pathologically similar to psoriasis.[1] Since the approval of the mRNA vaccines for SARS-CoV-2, multiple cutaneous adverse events were associated with the administration of the vaccine.[[2]] We report a case of recalcitrant PRP following administration of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech). Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin The patient also reported no personal or family history of psoriasis, PRP, or other autoimmune disease. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.